AUR-AD9E-TTM2-A-1-1-R-A542-39
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.380
- ESTROGEN_RESPONSE_LATE+0.300
- TGF_BETA_SIGNALING+0.270
- HEDGEHOG_SIGNALING+0.210
- WNT_BETA_CATENIN_SIGNALING+0.210
- MYC_TARGETS_V2+0.130
- MYOGENESIS+0.120
- ANGIOGENESIS+0.100
- APICAL_JUNCTION+0.020
- MITOTIC_SPINDLE+0.020
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- INTERFERON_GAMMA_RESPONSE-0.540
- ALLOGRAFT_REJECTION-0.490
- INFLAMMATORY_RESPONSE-0.440
- IL6_JAK_STAT3_SIGNALING-0.410
- TNFA_SIGNALING_VIA_NFKB-0.400
- MTORC1_SIGNALING-0.380
- E2F_TARGETS-0.330
- IL2_STAT5_SIGNALING-0.330
- COMPLEMENT-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ea89121f-2c74-433d-8047-898dc963bf35 | — | — | 0.837 |
| 2 | AUR-AD9E-TTM4-A-1-1-R-A542-39 | — | B | 0.829 |
| 3 | 302722c6-102e-4b1b-845e-78920380e337 | — | — | 0.822 |
| 4 | TCGA-AC-A2FM-01A-11R-A19W-07 | — | B | 0.822 |
| 5 | MNG660 | — | — | 0.821 |
| 6 | 4e24bc58-d246-4c96-952a-a18f95d142b2 | — | — | 0.814 |
| 7 | SRR8392885 | — | cohortA3 | 0.812 |
| 8 | SRR5088871 | — | — | 0.811 |
| 9 | SRR8518202 | — | A | 0.811 |
| 10 | TCGA-A8-A09B-01A-11R-A00Z-07 | — | B | 0.810 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.380 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.130 | Idelalisib | — uncovered |
| MYOGENESIS | 0.120 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.020 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.020 | Inavolisib | — uncovered |